OBJECTIVE: Receptors for estrogen (ER) and progesterone (PR) are prognostic indicators for a variety of endocrine tumors including breast and endometrial. This study was conducted to determine if ER and PR expression patterns are predictive of outcome in patients with epithelial ovarian cancer (EOC) or ovarian low malignant potential (LMP) tumors. METHODS: ER and PR protein levels were assessed by immunohistochemistry in 45 LMP and 89 EOC samples. Patterns of ER/PR expression (individually and combinations of ER-/PR-, ER+/PR-, ER-/PR+, and ER+/PR+) were correlated with standard prognostic factors of overall survival (OS) in this patient population. RESULTS: For patients with EOC, the 5-year OS per ER-/PR+, ER+/PR-, ER+/PR+, and ER-/PR- expression was 83%, 79%, 61%, and 48%, respectively, and these differences were statistically significant. In multivariate analyses, ER/PR expression patterns were found to be independent predictors of OS, as were the classical prognostic factors of grade, stage, debulking, and chemotherapy response to treatment. In patients with mucinous LMP tumors, ER and PR were absent. Because no LMP patients died of disease during the studied period, no correlation analysis with OS could be performed. CONCLUSIONS: Patterns of ER/PR expression provide prognostic information in EOC. Additional studies evaluating hormonal inhibition may help personalize the therapy of patients with ovarian cancer.
OBJECTIVE: Receptors for estrogen (ER) and progesterone (PR) are prognostic indicators for a variety of endocrine tumors including breast and endometrial. This study was conducted to determine if ER and PR expression patterns are predictive of outcome in patients with epithelial ovarian cancer (EOC) or ovarian low malignant potential (LMP) tumors. METHODS: ER and PR protein levels were assessed by immunohistochemistry in 45 LMP and 89 EOC samples. Patterns of ER/PR expression (individually and combinations of ER-/PR-, ER+/PR-, ER-/PR+, and ER+/PR+) were correlated with standard prognostic factors of overall survival (OS) in this patient population. RESULTS: For patients with EOC, the 5-year OS per ER-/PR+, ER+/PR-, ER+/PR+, and ER-/PR- expression was 83%, 79%, 61%, and 48%, respectively, and these differences were statistically significant. In multivariate analyses, ER/PR expression patterns were found to be independent predictors of OS, as were the classical prognostic factors of grade, stage, debulking, and chemotherapy response to treatment. In patients with mucinous LMP tumors, ER and PR were absent. Because no LMPpatients died of disease during the studied period, no correlation analysis with OS could be performed. CONCLUSIONS: Patterns of ER/PR expression provide prognostic information in EOC. Additional studies evaluating hormonal inhibition may help personalize the therapy of patients with ovarian cancer.
Authors: Lisa A Carey; E Claire Dees; Lynda Sawyer; Lisa Gatti; Dominic T Moore; Frances Collichio; David W Ollila; Carolyn I Sartor; Mark L Graham; Charles M Perou Journal: Clin Cancer Res Date: 2007-04-15 Impact factor: 12.531
Authors: John F Smyth; Charlie Gourley; Graeme Walker; Melanie J MacKean; Alan Stevenson; Alistair R W Williams; Awatif Al Nafussi; Tzyvia Rye; Ron Rye; Moira Stewart; Janet McCurdy; Max Mano; Nick Reed; Tracey McMahon; Paul Vasey; Hani Gabra; Simon P Langdon Journal: Clin Cancer Res Date: 2007-06-15 Impact factor: 12.531
Authors: H Gabra; J E Watson; K J Taylor; J Mackay; R C Leonard; C M Steel; D J Porteous; J F Smyth Journal: Cancer Res Date: 1996-03-01 Impact factor: 12.701
Authors: P Pujol; J M Rey; P Nirde; P Roger; M Gastaldi; F Laffargue; H Rochefort; T Maudelonde Journal: Cancer Res Date: 1998-12-01 Impact factor: 12.701
Authors: David M Gershenson; Charlotte C Sun; Revathy B Iyer; Anais L Malpica; John J Kavanagh; Diane C Bodurka; Kathleen Schmeler; Michael Deavers Journal: Gynecol Oncol Date: 2012-03-06 Impact factor: 5.482
Authors: Nabila Chaher; Hugo Arias-Pulido; Nadija Terki; Clifford Qualls; Kamel Bouzid; Claire Verschraegen; Anne Marie Wallace; Melanie Royce Journal: Breast Cancer Res Treat Date: 2011-03-01 Impact factor: 4.872
Authors: Monique A Spillman; Nicole G Manning; Wendy W Dye; Carol A Sartorius; Miriam D Post; Joshua Chuck Harrell; Britta M Jacobsen; Kathryn B Horwitz Journal: Cancer Res Date: 2010-10-19 Impact factor: 12.701
Authors: Luis Felipe Sallum; Luis Otavio Sarian; Liliana Lucci De Angelo Andrade; José Vassallo; Fernando Augusto Soares; Glauce Aparecida Pinto; Patrícia Andréia Ferreira; Sophie Derchain Journal: J Gynecol Oncol Date: 2013-04-05 Impact factor: 4.401
Authors: Stefanie Aust; Anna Bachmayr-Heyda; Petra Pateisky; Dan Tong; Silvia Darb-Esfahani; Carsten Denkert; Radoslav Chekerov; Jalid Sehouli; Sven Mahner; Toon Van Gorp; Ignace Vergote; Paul Speiser; Reinhard Horvat; Robert Zeillinger; Dietmar Pils Journal: Mol Cancer Date: 2012-09-14 Impact factor: 27.401
Authors: Julie E Bauman; Keith D Eaton; Sarah G Wallace; Laurie L Carr; Sang-Joon Lee; Dennie V Jones; Hugo Arias-Pulido; Lisa A Cerilli; Renato G Martins Journal: BMC Cancer Date: 2012-10-03 Impact factor: 4.430